BioCentury
ARTICLE | Top Story

Janssen seeking to block Remicade biosimilar

March 11, 2015 1:34 AM UTC

A suit filed by the Janssen Inc. unit of Johnson & Johnson (NYSE:JNJ) and by New York University against Celltrion Inc. (KOSDAQ:068270) and Hospira Inc. (NYSE:HSP) seeks to delay or block the U.S. launch of CT-P13, a biosimilar of J&J's autoimmune drug Remicade infliximab.

The suit, filed in the U.S. District Court for the District of Massachusetts, alleges Celltrion and Hospira did not comply with the Biologics Price Competition and Innovation Act (BPCIA). The plaintiffs also allege infringement of six Janssen patents, including two co-owned by NYU. Among them is U.S. Patent No. 6,284,471, which the U.S. Patent and Trademark Office rejected in February. J&J said on Feb. 12 that it had 60 days to respond to the rejection, and planned to do so. ...